A Study of SH009 Injection in Patients With Advanced Solid Tumors.

Evaluate the efficacy and safety of SH009 injection therapy for patients with advanced solid tumors

Trial Details

NCT ID
NCT07390838
Phase
PHASE1
Sponsor
Nanjing Sanhome Pharmaceutical, Co., Ltd.
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • SH009
Locations (sample)
  • Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

  • (1) Age≥18 years old at the time of informed consent, male or female;
  • (2) Subjects with histologically confirmed locally advanced, recurrent, or metastatic solid tumors (including but not limited to colorectal cancer,…
  • (3) Subjects must have at least one measurable lesion per RECIST 1.1 criteria. A lesion that has been previously irradiated can only be considered …
  • (4) Archival tumor tissue samples are available, or the subject agrees to undergo a tumor biopsy for the determination of PD-L1 and CD47 expression…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →